Test del ADN fecal para la detección del cáncer colorrectal

1. Siegel RL,Miller KD, Jemal A. 2019. Cancer statistics, 2019. CA Cancer J. Clin. 69:7–34

2. Nishihara R,Wu K, Lochhead P, et al. 2013. Long-term colorectal-cancer incidence and mortality after lower endoscopy.N. Engl. J. Med. 369:1095–105

3. Zauber A,Winawer SJ,O’Brien MJ, et al. 2012. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths.N. Engl. J. Med. 366:687–96

4. Shaukat A, Mongin SJ,GeisserMS, et al. 2013. Long-termmortality after screening for colorectal cancer. N. Engl. J. Med. 369:1106–14

5. Rex DK, Boland CR, Dominitz JA, et al. 2017. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology 153:307–23

6. Carethers JM. 2015. Screening for colorectal cancer in African Americans: determinants and rationale for an earlier age to commence screening. Digest. Dis. Sci. 60:711–21

7. Ahlquist DA. 2015. Multi-target stool DNA test: a new high bar for noninvasive screening. Digest. Dis. Sci. 60:623–33

8. Lin JS, Webber EM, Beil TL, et al. 2012. Fecal DNA testing in screening for colorectal cancer in averagerisk adults: comparative effectiveness review. Executive summary no. 52. AHRQ Pub. No. 12-EHC022-1. Rockville, MD: Agency for Healthcare Research and Quality. https://effectivehealthcare.ahrq.gov/sites/default/files/related_files/colorectal-cancer-screening_executive.pdf. Accessed June 1, 2019

9. Carethers JM. 2014. DNA testing and molecular screening for colon cancer. Clin. Gastroenterol. Hepatol. 12:377–8110. Grady WM, Carethers JM. 2008. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135:1079–99

11. Carethers JM, Jung BH. 2015. Genetics and genetic biomarkers in sporadic colorectal cancer. Gastroenterology 149:1177–90

12. Cancer Genome Atlas Network. 2012. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330–37

13. Carethers JM. 2016. Hereditary, sporadic and metastatic colorectal cancers are commonly driven by specific spectrums of defective DNA mismatch repair components. Trans. Am. Clin. Climatol. Assoc. 127:81–97

14. Carethers JM. 2017. Microsatellite instability pathway and EMAST in colorectal cancer. Curr. Colorectal Cancer Rep. 13:73–80

15. Carethers JM, Fearon ER. 2015. Molecular subtyping of colorectal cancer: time to explore both intertumoral and intratumoral heterogeneity to evaluate patient outcome. Gastroenterology 148:10–13

16. Koi M, Garcia M, Choi C, et al. 2016. Microsatellite alterations with allelic loss on 9p24.2 signify les aggressive colorectal cancer metastasis. Gastroenterology 150:944–55

17. Coppede F, Lopomo A, Spisni R, Migliore L. 2014. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer.World J. Gastroenterol. 20:943–56

18. Carethers JM. 2015. Biomarker-directed targeted therapy in colorectal cancer. J. Digest. Cancer Rep. 3:5–10

19. Klaassen CH, JeuninkMA, Prinsen CR, et al. 2003. Quantification of human DNA in feces as a diagnostic test for the presence of colorectal cancer. Clin. Chem. 49:1185–87

20. Anderson BW, Ahlquist DA. 2016. Molecular detection of gastrointestinal neoplasia. Gastroenterol. Clin. N. Am. 45:529–42

21. Sidransky D, Tokino T, Hamilton SR, et al. 1992. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 256:102–5

22. Zou H,Taylor WR, Harrington JJ, et al. 2009. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology 136:459–70

23. Ahlquist DA, Sargent DJ, Loprinzi CL, et al. 2008. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann. Intern.Med. 149:441–50

24. Shen L, Toyota M, Kondo Y, et al. 2007. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl. Acad. Sci. USA 104:18654–59

25. Imperiale TF,Ransohoff DF, Itzkowitz SH, et al. 2004. FecalDNAversus fecal occult blood for colorectal cancer screening in an average-risk population.N. Engl. J. Med. 35:2704–14